ArticleRenal failure2026
Impact of combined ECMO - CRRT support on patient outcomes and risk factors: a multicenter retrospective study.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lactate in acute kidney injury: pathobiology, risk stratification, and clinical interpretation.Renal failure · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the association of continuous renal replacement therapy (CRRT) use with the prognosis of patients undergoing extracorporeal membrane oxygenation (ECMO) and to explore its relationship with changes in blood cell components.
methodsData from four tertiary hospitals in China were retrospectively reviewed for patients who received ECMO support between September 2019 and June 2024. Univariable and multivariable logistic and Cox regression analyses were used to identify factors associated with in-hospital mortality. As an exploratory analysis, peripheral blood cell counts over the first 4 days after ECMO initiation were compared between groups, with hemoglobin and platelet values adjusted for transfusions.
resultsAmong 158 ECMO patients, 89 received CRRT and 69 did not, with an overall in-hospital mortality of 41.1%. Mortality was higher in the CRRT+ group than in the CRRT - group (53.9% vs. 24.6%,
conclusionsCRRT use was linked to poorer prognosis in ECMO patients, including higher in-hospital mortality, and was associated with marked changes in blood cell components.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.